Abstract:17099 Background: Prolonged infusion of gemcitabine have shown increased levels of the active triphosphate metabolite that theorically could increase the response rate and toxicity. The objectives of this study were to evaluated the efficacy and safety of this combination of using gemcitabine as a rate infusion of 10 mg/m2 per min with carboplatin in front-line chemonaive patients with advanced NSCLC. Methods: Fifty-four chemonaive patients have been included. 44 were male and 10 female. Median age was 63 years (19–75). 13% had ECOG 0 and 53.7% ECOG 1 and 33.3% ECOG 2. 32 (59.2%) patients had adenocarcinoma, 13 (24.1%) squamous cell, 1 (1.9%) large cell carcinoma, and 8 (14.8%) others. Eight (14.8%) had stage IIIB and 46 (85.2%) stage IV. Treatment was consisted of 1200 mg/m2 gemcitabine given as a 2-hour continuous infusion (10 mg/m2 per min) on days 1 and 8 of each cycle an AUC 5 carboplatin as on day 1, repeating each cycle every 21 days. A total of 223 chemotherapy cycles were administered, with a median of 4 cycles per patient (range 1–6), and 15 (27.8%) patients received all six cycles. Results: Of the fifty-four patients enrolled, all were evaluated for toxicity (according to the WHO scale) and 51 assessed for response (according to the RECIST criteria), the overall response rate (ORR) was 41.2% (95% confidence interval, 28% to 57%), including two complete responses (CRs: 3.9%) and 19 partial responses (PRs: 37.3%). As per the intent-to-treat (ITT) analysis, the ORR was 38.9%. With a median follow-up time of 10.8 months, the median TTP was 5.0 months (range 3.7–6.3 months), median OS time was 11.5 months (range 9.9–13.1 months) and 1-year survival was 41.7% (95% CI 26% to 57%) and 2-year survival was 19.3% (4.4% to 34.2%).The main grade 3–4 toxicity consisted of neutropenia (55.6%) and thrombocytopenia (57.4%).Patients were required platelet transfusion in 27 cycles (12.1%) and haematopoietic growth factors support care in 56 (25.1%) cycles. No bleeding episodes were recorded. Grade 3 nausea/vomiting occurred in 5.6% and grade 1–2 skin rash occurred in 42.6%. Conclusions: Prolonged gemcitabine infusion combined with carboplatin is manageable tolerated and its efficacy is similar to that of other chemotherapeutic schemes used for NSCLC treatment. No significant financial relationships to disclose.

Clinical Evaluation of delayed infusion of low dose gemcitabine combined with cisplatin maintenance chemotherapy regimens for treatment of advanced NSCLC patients

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Clinical Observation of Gemcitabine Combined with Cisplatin As Second- or Third-Line on Patients with Advanced Triple-Negative Breast Cancer

Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Comparasion on Two Combination Regimens of Nedaplatin Plus Gemcitabine and Cisplatin Plus Gemcitabine for Treatment of Patients with Advanced Non Small-cell Lung Cancer

Comparison of Pharmacokinetics, Efficacy and Toxicity Profile of Gemcitabine Using Two Different Administration Regimens in Chinese Patients with Non-Small-cell Lung Cancer

The Efficacy and Relationship Between Peak Concentration and Toxicity Profile of Fixed-Dose-Rate Gemcitabine Plus Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

Randomized trial of gemcitabine plus cisplatin versus paclitaxel plus cisplatin in treating advanced non-small cell lung cancer

[Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer].

Study of Feasibility of Endostar Plus Gemcitabine and Cisplatin Regimen for Advanced Non-Small Cell Lung Cancer

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

Phase II Trial of Gemcitabine Plus Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer

Influences of China-Made Gemcitabine Plus Platinum Regimen on the Quality of Life among Patients with Advanced Non-Small Cell Lung Cancer

Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.

A Retrospective Analysis to Explore the Value of Gemcitabine Combined with Cisplatin As Adjuvant Chemotherapy of NSCLC

Three Cisplatin-Based Regimens in Treatment of Advanced Non-Small Cell Lung Cancer

Compare and Evaluate Two Combination Regimens of Vinorelbine Plus Gemcitabine and Cisplatin Pins Vinorelbine for Treatment of Patients with Advanced Non-Small-cell Lung Cancer